转移性前列腺癌中18F-DCFPyL、18F-NaF与18F-FDG PET/CT的前瞻性队列比较
结果显示18F-NaF检出骨转移灶数多于18F-DCFPyL,而18F-DCFPyL检出病灶数多于18F-FDG;两种示踪剂间病灶一致率有限,提示转移灶表型异质性。
要点
- 18F-NaF检出转移性病灶数显著多于18F-DCFPyL(中位3 vs 2,P=0.001)。
- 18F-DCFPyL检出病灶数显著多于18F-FDG(中位5 vs 2,P=0.0003)。
- 18F-DCFPyL与18F-NaF骨病灶中位一致率50%,与18F-FDG中位一致率22.2%。
核心结论
- 18F-DCFPyL PET/CT是三种PET显像剂中用于转移性前列腺癌最通用的,但18F-NaF检出更多骨转移灶。
- 显像显示肿瘤异质性显著,18F-DCFPyL与18F-NaF一致率仅50%,与18F-FDG一致率约22%。
研究设计与样本
- 其中30例(组2)额外行18F-FDG PET/CT。
主要发现
- 61例在一项或多项扫描中检出转移性疾病,6例所有PET/CT均无疾病摄取并随后被排除分析。
- 组1中18F-NaF检出转移性病灶数显著多于18F-DCFPyL(中位3 vs 2,P=0.001),在治疗中(P=0.005)或去势抵抗(P=0.014)男性中差异尤其明显。
- 18F-DCFPyL与18F-NaF骨病灶中位一致率为50%。
- 组2中18F-DCFPyL检出病灶数多于18F-FDG(中位5 vs 2,P=0.0003),不受PSA水平、去势状态或治疗影响。
- 18F-DCFPyL与18F-FDG病灶中位一致率为22.2%,去势抵抗男性略高于去势敏感男性(P=0.048)。
关键数值与推荐
- 18F-NaF与18F-DCFPyL检出转移性病灶数比较:中位3 vs 2,P=0.001。
- 18F-DCFPyL与18F-FDG检出病灶数比较:中位5 vs 2,P=0.0003。
- 18F-DCFPyL与18F-NaF骨病灶中位一致率50%;18F-DCFPyL与18F-FDG病灶中位一致率22.2%。
临床怎么用
- 18F-DCFPyL PET/CT可作为转移性前列腺癌通用显像选择,但需注意其骨转移检出可能少于18F-NaF。
- 18F-NaF在治疗中或去势抵抗患者中检出更多骨病灶,可考虑互补使用。
- 示踪剂间一致率有限提示转移灶表型异质性,单一显像可能低估病灶范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
18F-DCFPyL, 18F-sodium fluoride (18F-NaF), and 18F-FDG PET/CT were compared in a prospective cohort of men with metastatic prostate cancer (PCa). Methods: Sixty-seven men (group 1) with documented metastatic PCa underwent 18F-DCFPyL and 18F-NaF PET/CT and a subgroup of 30 men (group 2) underwent additional imaging with 18F-FDG PET/CT. The tracers were compared for their detection rates, imaging concordance, associations with prostate-specific antigen (PSA), treatment at the time of imaging, and castration status. Results: Overall, 61 men had metastatic disease detected on one or more scans, and 6 men had no disease uptake on any of the PET/CT scans (and were subsequently excluded from the analysis). In group 1, 18F-NaF detected significantly more metastatic lesions than 18F-DCFPyL (median of 3 lesions vs. 2, P = 0.001) even after eliminating benign causes of 18F-NaF uptake. This difference was particularly clear for men receiving treatment (P = 0.005) or who were castration-resistant (P = 0.014). The median percentage of bone lesions that were concordant on 18F-DCFPyL and 18F-NaF was 50%. In group 2, 18F-DCFPyL detected more lesions than 18F-FDG (median of 5 lesions vs. 2, P = 0.0003), regardless of PSA level, castration status, or treatment. The median percentage of lesions that were concordant on 18F-DCFPyL and 18F-FDG was 22.2%. This percentage was slightly higher for castration-resistant than castration-sensitive men (P = 0.048). Conclusion:18F-DCFPyL PET/CT is the most versatile of the 3 PET agents for metastatic PCa; however, 18F-NaF detects more bone metastases. Imaging reveals substantial tumor heterogeneity with only 50% concordance between 18F-DCFPyL and 18F-NaF and 22% concordance for 18F-DCFPyL and 18F-FDG. These findings indicate considerable phenotypic differences among metastatic lesions.
引用
- Fourquet A, Rosenberg A, Mena E, et al. A Comparison of 18F-DCFPyL, 18F-NaF, and 18F-FDG PET/CT in a Prospective Cohort of Men with Metastatic Prostate Cancer. J Nucl Med. 2021. PMID: 34475237. doi:10.2967/jnumed.121.262371
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。